罗格列酮对阿尔茨海默病治疗作用的Meta分析

J4 ›› 2012, Vol. 38 ›› Issue (2): 296-302.

罗格列酮对阿尔茨海默病治疗作用的Meta分析

姚燕¹|张天一^１,2,杨芳²|郭蔚莹³|张晴晴¹|于雅琴¹

1. 吉林大学公共卫生学院流行病与卫生统计学教研室|吉林长春 130021；2．吉林大学第一医院健康促进中心|吉林长春 130021；3.吉林大学第一医院内分泌科| 吉林长春 130021

收稿日期:2011-12-25 出版日期:2012-03-28 发布日期:2012-03-28
通讯作者: 杨芳（Tel：0431-88782122， E-mail： yangfang7164@yahoo.com.cn） E-mail:yangfang7164@yahoo.com.cn
作者简介:姚燕（1982-）|女|山西省太原市人|讲师|医学博士|在站博士后|主要从事临床流行病学研究。
基金资助:
中央高校基本科研业务费专项资金资助课题（450060445260）

Meta-analysis on effect of rosiglitazone in treatment of Alzheimer’s disease

YAO Yan¹,ZHANG Tian-yi^1,2,YANG Fang^2,GUO Wei-ying^3,ZHANG Qing-qing^1,YU Ya-qin^1

1. Department of Epidemiology and Health Statistics,School of Public Health,Jilin University,Changchun 130021,China;2. Center of Health Promotion,First Hospital,Jilin University,Changchun 130021,China|3. Department of Endocrinology,First Hospital,Jilin University,Changchun 130021,China

Received:2011-12-25 Online:2012-03-28 Published:2012-03-28

摘要/Abstract

摘要：

目的：探讨PPAR-γ激活剂——罗格列酮对阿尔茨海默病（AD）的治疗作用,为临床上阿尔茨海默病治疗方案的选择提供指导。方法：按照系统评价的要求全面检索Medline、中国学术期刊全文数据库（CNKI），搜集有关罗格列酮治疗AD的随机对照试验（RCT）或临床对照试验（CCT）；由2名评价员独立筛选、评价文献和提取数据；用Review Manager 5.0软件对符合纳入标准的3篇文献进行Meta分析。结果：共有8项RCT入选本次研究。罗格列酮与安慰剂治疗AD的ADAS-cog评分变化比较差异有统计学意义（WMD=－0.39，95%CI＝－0.69～－0.08,P=0.01）。罗格列酮与安慰剂治疗AD的安全性比较差异无统计学意义（OR=1.16，95%CI=0.97～1.37），P=0.10）。按照治疗剂量分层进行亚组分析发现，服用8 mg罗格列酮发生不良反应的风险是服用安慰剂的1.33倍（OR值95%CI=1.13～1.56）。结论：罗格列酮在一定程度上可改善AD患者的认知功能，但应用时需要考虑其安全性。

关键词: 罗格列酮；阿尔茨海默病；Meta分析

Abstract:

Objective
To explore the effect of rosiglitazone in the treatment of Alzheimer’s disease(AD) and provide guidance for AD treatment. Methods A thorough literature search related to randomized controlled trial(RCT) or clinical controlled trial(CCT) on treatment of AD with rosiglitazone was performed among Medline and database of CNKI in accordance with the requirements of Cochrane systematic review. Two reviewers reviewed the original articles,abstracted data and assigned an initial quality rating independently. With RevMan 5.0 software,Meta-analysis was carried out on the three literatures which were accorded with the criterion. Results Eight studies were included. All the studies reported and measured the changes in ADAS-cog score from baseline to endpoint for active treatment compared with placebo and there was a significant difference between two groups（WMD=－0.39，95%CI=－0.69－－0.08,P=0.01）. No significant difference of safety was detected between placebo and treatment groups（OR=1.16，95%CI＝0.97－1.37，P=0.10）. But a significant difference was observed when the data was stratified by dosage,the incidence of adverse events in patients who took 8 mg rosiglitazone everyday was roughly as 1.33 times as those who took placebo（OR95%CI＝1.13－1.56）. Conclusion Rosiglitazone can to some extent improve cognitive function of AD patients. However,the safety should be considered when it is applied.

Key words: rosiglitazone；Alzheimer’s disease；Meta-analysis

中图分类号:

R749.16

姚燕|张天一,2,杨芳|郭蔚莹|张晴晴|于雅琴. 罗格列酮对阿尔茨海默病治疗作用的Meta分析[J]. J4, 2012, 38(2): 296-302.

YAO Yan,ZHANG Tian-yi,YANG Fang,GUO Wei-ying,ZHANG Qing-qing,YU Ya-qin. Meta-analysis on effect of rosiglitazone in treatment of Alzheimer’s disease[J]. J4, 2012, 38(2): 296-302.